1
|
Aujay M, Broad AJ, Gross SD, Ren L, Lyssikatos JP, Kintz S, Wang Q, Collins H. Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Mutation or amplification of the human epidermal growth factor receptor 2 (HER2) gene has been identified in numerous solid tumor types, including non-small cell lung cancer (NSCLC), breast, and colorectal cancer. These genetic alterations are believed to confer elevated HER2 activity resulting in oncogenic transformation. In NSCLC, an estimated 3% of patients harbor activating mutations in the HER2 gene. Enhertu (T-DXd), a HER2-specific antibody-drug conjugate was recently approved as an important therapy for this patient population. However, for patients who are not candidates for T-DXd or have discontinued treatment due to an adverse event or disease progression, there exist few therapeutic options. Accordingly, HER2 inhibitors have the potential to provide meaningful therapeutic benefit to these patients. Due to significant structural homology between EGFR and HER2, most investigational small molecule HER2 kinase inhibitors are dual EGFR/HER2 inhibitors and are substantially dose-limited by EGFR-related toxicities in patients. These toxicities likely limit their clinical activity. Currently, tucatinib is the only HER2-selective small molecule inhibitor approved for metastatic breast cancer in combination with trastuzumab and capecitabine. However, it lacks sufficient potency against several of the key clinically relevant mutations, including HER2 YVMA, the most common exon 20 insertion mutation, prevalent in HER2 mutant NSCLC. ELVN-002 is a potent, irreversible inhibitor of HER2 with a >100-fold selectivity over EGFR. ELVN-002 potently inhibits the phosphorylation of HER2 in cell lines endogenously expressing HER2 or in those engineered to express specific clinically relevant HER2 mutants. This activity readily translates into marked anti-proliferative activity against cell lines dependent upon HER2 for their growth and survival. In addition, ELVN-002 is highly selective for HER2 and HER2 mutants versus wild-type EGFR as demonstrated via assessment of both EGFR-driven proliferation and EGFR phosphorylation in cells. Furthermore, ELVN-002 is highly active in mouse models of HER2-driven cancers, including subcutaneous models driven by wild type or mutant HER2. ELVN-002 is also active in an NCI-N87 wild-type HER2 intracranial model. In all models tested, ELVN-002 treatment is well tolerated and resulted in tumor regressions at exposures believed to be clinically achievable. Due to its selectivity and breadth of activity versus the clinically relevant HER2 mutants, ELVN-002 has the potential to be an effective treatment for HER2 mutant NSCLC as well as other HER2 mutant amplified solid tumors, including metastatic HER2 positive breast cancer. Additionally, ELVN-002 could provide a meaningful therapeutic option for patients with CNS metastases. ELVN-002 has been selected for clinical development.
Citation Format: Monette Aujay, Amanda J. Broad, Stefan D. Gross, Li Ren, Joseph P. Lyssikatos, Samuel Kintz, Qi Wang, Helen Collins. Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4019.
Collapse
Affiliation(s)
| | | | | | - Li Ren
- 1Enliven Therapeutics, Boulder, CO
| | | | | | - Qi Wang
- 1Enliven Therapeutics, Boulder, CO
| | | |
Collapse
|
2
|
Holte D, Lyssikatos JP, Valdiosera AM, Swinney Z, Sisodiya V, Sandoval J, Lee C, Aujay MA, Tchelepi RB, Hamdy OM, Gu C, Lin B, Sarvaiya H, Pysz MA, Laysang A, Williams S, Jun Lee D, Holda MK, Purcell JW, Gavrilyuk J. Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg Med Chem Lett 2020; 30:127640. [PMID: 33127540 DOI: 10.1016/j.bmcl.2020.127640] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 10/13/2020] [Accepted: 10/21/2020] [Indexed: 11/18/2022]
Abstract
PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its extremely high potency and only partially understood mechanism of action, it was deemed an interesting starting point for the development of a new suite of linker drugs for antibody drug conjugates (ADCs). Structure activity relationships were explored on the small molecule which led to six linker drugs being developed for conjugation to antibodies. Herein we describe the synthesis of novel PNU-159682 derivatives and the subsequent linker drugs as well as the corresponding biological evaluations of the small molecules and ADCs.
Collapse
Affiliation(s)
- Dane Holte
- AbbVie Chemical Development & Manufacturing, 995 East Arques Avenue, Sunnyvale, CA 94085, USA.
| | - Joseph P Lyssikatos
- Enliven Therapeutics, 6200 Lookout Road, First Floor, Boulder, CO 80301, USA
| | | | - Zachary Swinney
- Mantra Bio, 455 Mission Bay Boulevard, South San Francisco, CA 94158, USA
| | - Vikram Sisodiya
- Denali Therapeutics, 161 Oyster Point Bloulevard, South San Francisco, CA 94080, USA
| | - Joseph Sandoval
- Fate Therapeutics, 3535 General Atomics Court, Suite 200, San Diego 92121, USA
| | - Christina Lee
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| | - Monette A Aujay
- Enliven Therapeutics, 6200 Lookout Road, First Floor, Boulder, CO 80301, USA
| | - Robert B Tchelepi
- Bolt Biotherapeutics, 640 Galveston Drive, Redwood City, CA 94063, USA
| | - Omar M Hamdy
- Applied Molecular Transport, 1 Tower Place, Suite 850, South San Francisco, CA 94080, USA
| | - Christine Gu
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA; AbbVie Research & Development, 995 East Arques Avenue, Sunnyvale, CA 94085, USA
| | - Baiwei Lin
- Maze Therapeutics, 131 Oyster Point Blvd, Suite 200, South San Francisco, CA 94080, USA
| | - Hetal Sarvaiya
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| | - Marybeth A Pysz
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| | - Amy Laysang
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| | - Samuel Williams
- ArsenalBio, Inc. 2 Tower Place, South San Francisco, CA 94080, USA
| | - Dong Jun Lee
- AbbVie Research & Development, 995 East Arques Avenue, Sunnyvale, CA 94085, USA
| | - Magda K Holda
- AbbVie Research & Development, 1500 Seaport Blvd, Redwood City, CA 94063, USA
| | - James W Purcell
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| | - Julia Gavrilyuk
- AbbVie Research & Development, 400 East Jamie Court, South San Francisco, CA 94080, USA
| |
Collapse
|
3
|
Zak M, Hanan EJ, Lupardus P, Brown DG, Robinson C, Siu M, Lyssikatos JP, Romero FA, Zhao G, Kellar T, Mendonca R, Ray NC, Goodacre SC, Crackett PH, McLean N, Hurley CA, Yuen PW, Cheng YX, Liu X, Liimatta M, Kohli PB, Nonomiya J, Salmon G, Buckley G, Lloyd J, Gibbons P, Ghilardi N, Kenny JR, Johnson A. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorg Med Chem Lett 2019; 29:1522-1531. [PMID: 30981576 DOI: 10.1016/j.bmcl.2019.04.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Revised: 03/27/2019] [Accepted: 04/03/2019] [Indexed: 01/22/2023]
Abstract
Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
Collapse
Affiliation(s)
- Mark Zak
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
| | - Emily J Hanan
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | - David G Brown
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Colin Robinson
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Michael Siu
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | - Guiling Zhao
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Terry Kellar
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Rohan Mendonca
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Nicholas C Ray
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Simon C Goodacre
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Peter H Crackett
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Neville McLean
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Christopher A Hurley
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Po-Wai Yuen
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Yun-Xing Cheng
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Xiongcai Liu
- Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China
| | - Marya Liimatta
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Pawan Bir Kohli
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Jim Nonomiya
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Gary Salmon
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Gerry Buckley
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Julia Lloyd
- Charles River Laboratories, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom
| | - Paul Gibbons
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Nico Ghilardi
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Jane R Kenny
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Adam Johnson
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| |
Collapse
|
4
|
Wang X, Blackaby W, Allen V, Chan GKY, Chang JH, Chiang PC, Diène C, Drummond J, Do S, Fan E, Harstad EB, Hodges A, Hu H, Jia W, Kofie W, Kolesnikov A, Lyssikatos JP, Ly J, Matteucci M, Moffat JG, Munugalavadla V, Murray J, Nash D, Noland CL, Del Rosario G, Ross L, Rouse C, Sharpe A, Slaga D, Sun M, Tsui V, Wallweber H, Yu SF, Ebens AJ. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. J Med Chem 2019; 62:2140-2153. [DOI: 10.1021/acs.jmedchem.8b01857] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Xiaojing Wang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wesley Blackaby
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Vivienne Allen
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Grace Ka Yan Chan
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jae H. Chang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Po-Chang Chiang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Coura Diène
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Jason Drummond
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Steven Do
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Eric Fan
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Eric B. Harstad
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Alastair Hodges
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Huiyong Hu
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wei Jia
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - William Kofie
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Aleksandr Kolesnikov
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Joseph P. Lyssikatos
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Justin Ly
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Mizio Matteucci
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - John G. Moffat
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | | | - Jeremy Murray
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - David Nash
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Cameron L. Noland
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Geoff Del Rosario
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Leanne Ross
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Craig Rouse
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Andrew Sharpe
- Charles River Discovery Research Services UK Limited (formerly BioFocus), Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom
| | - Dionysos Slaga
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Minghua Sun
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Vickie Tsui
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Heidi Wallweber
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Shang-Fan Yu
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Allen J. Ebens
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
5
|
Chen H, Volgraf M, Do S, Kolesnikov A, Shore DG, Verma VA, Villemure E, Wang L, Chen Y, Hu B, Lu AJ, Wu G, Xu X, Yuen PW, Zhang Y, Erickson SD, Dahl M, Brotherton-Pleiss C, Tay S, Ly JQ, Murray LJ, Chen J, Amm D, Lange W, Hackos DH, Reese RM, Shields SD, Lyssikatos JP, Safina BS, Estrada AA. Discovery of a Potent (4R,5S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling. J Med Chem 2018; 61:3641-3659. [DOI: 10.1021/acs.jmedchem.8b00117] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Yong Chen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Baihua Hu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Ai-Jun Lu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Guosheng Wu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Xiaofeng Xu
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Po-wai Yuen
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Yamin Zhang
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Shawn D. Erickson
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Martin Dahl
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Christine Brotherton-Pleiss
- Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | | | | | | | | | - Desiree Amm
- Ion Channels Group, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Wienke Lange
- Ion Channels Group, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
6
|
Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M. Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. J Med Chem 2017; 60:8083-8102. [PMID: 28929759 DOI: 10.1021/acs.jmedchem.7b00843] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Significant data exists to suggest that dual leucine zipper kinase (DLK, MAP3K12) is a conserved regulator of neuronal degeneration following neuronal injury and in chronic neurodegenerative disease. Consequently, there is considerable interest in the identification of DLK inhibitors with a profile compatible with development for these indications. Herein, we use structure-based drug design combined with a focus on CNS drug-like properties to generate compounds with superior kinase selectivity and metabolic stability as compared to previously disclosed DLK inhibitors. These compounds, exemplified by inhibitor 14, retain excellent CNS penetration and are well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain.
Collapse
Affiliation(s)
| | | | | | - Jinhua Chen
- Department of Chemistry, WuXi AppTec Co., Ltd. , 288 Fute Zhonglu, Wai Gao Qiao Free Trade Zone, Shanghai 200131, P. R. China
| | | | | | | | | | | | | | | | | | | | | | | | - Changyou Ma
- Department of Chemistry, WuXi AppTec Co., Ltd. , 288 Fute Zhonglu, Wai Gao Qiao Free Trade Zone, Shanghai 200131, P. R. China
| | | | | | | |
Collapse
|
7
|
Marcotte D, Rushe M, M Arduini R, Lukacs C, Atkins K, Sun X, Little K, Cullivan M, Paramasivam M, Patterson TA, Hesson T, D McKee T, May-Dracka TL, Xin Z, Bertolotti-Ciarlet A, Bhisetti GR, Lyssikatos JP, Silvian LF. Germinal-center kinase-like kinase co-crystal structure reveals a swapped activation loop and C-terminal extension. Protein Sci 2016; 26:152-162. [PMID: 27727493 DOI: 10.1002/pro.3062] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 10/10/2016] [Accepted: 10/10/2016] [Indexed: 12/20/2022]
Abstract
Germinal-center kinase-like kinase (GLK, Map4k3), a GCK-I family kinase, plays multiple roles in regulating apoptosis, amino acid sensing, and immune signaling. We describe here the crystal structure of an activation loop mutant of GLK kinase domain bound to an inhibitor. The structure reveals a weakly associated, activation-loop swapped dimer with more than 20 amino acids of ordered density at the carboxy-terminus. This C-terminal PEST region binds intermolecularly to the hydrophobic groove of the N-terminal domain of a neighboring molecule. Although the GLK activation loop mutant crystallized demonstrates reduced kinase activity, its structure demonstrates all the hallmarks of an "active" kinase, including the salt bridge between the C-helix glutamate and the catalytic lysine. Our compound displacement data suggests that the effect of the Ser170Ala mutation in reducing kinase activity is likely due to its effect in reducing substrate peptide binding affinity rather than reducing ATP binding or ATP turnover. This report details the first structure of GLK; comparison of its activation loop sequence and P-loop structure to that of Map4k4 suggests ideas for designing inhibitors that can distinguish between these family members to achieve selective pharmacological inhibitors.
Collapse
Affiliation(s)
- Douglas Marcotte
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Mia Rushe
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Robert M Arduini
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | | | - Kateri Atkins
- Beryllium Discovery Corp., 3 Preston Court, Bedford, MA, 01730
| | - Xin Sun
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Kevin Little
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Michael Cullivan
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Murugan Paramasivam
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Thomas A Patterson
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Thomas Hesson
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Timothy D McKee
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Tricia L May-Dracka
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Zhili Xin
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | | | - Govinda R Bhisetti
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Joseph P Lyssikatos
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| | - Laura F Silvian
- Department of Drug Discovery, Biogen Inc., 115 Binney Street, Cambridge, MA, 02142
| |
Collapse
|
8
|
Verma VA, Shore DG, Chen H, Chen J, Do S, Hackos DH, Kolesnikov A, Lyssikatos JP, Tay S, Wang L, Estrada AA. α-Aryl pyrrolidine sulfonamides as TRPA1 antagonists. Bioorg Med Chem Lett 2016; 26:495-498. [DOI: 10.1016/j.bmcl.2015.11.088] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Revised: 11/20/2015] [Accepted: 11/24/2015] [Indexed: 12/11/2022]
|
9
|
Ndubaku CO, Crawford JJ, Drobnick J, Aliagas I, Campbell D, Dong P, Dornan LM, Duron S, Epler J, Gazzard L, Heise CE, Hoeflich KP, Jakubiak D, La H, Lee W, Lin B, Lyssikatos JP, Maksimoska J, Marmorstein R, Murray LJ, O’Brien T, Oh A, Ramaswamy S, Wang W, Zhao X, Zhong Y, Blackwood E, Rudolph J. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett 2015; 6:1241-6. [PMID: 26713112 DOI: 10.1021/acsmedchemlett.5b00398] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 10/31/2015] [Indexed: 11/28/2022] Open
Abstract
Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pK a and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.
Collapse
Affiliation(s)
- Chudi O. Ndubaku
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - James J. Crawford
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Joy Drobnick
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Ignacio Aliagas
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - David Campbell
- Afraxis, Inc., 6605 Nancy Ridge
Road, Suite 224, San Diego, California 92121, United States
| | - Ping Dong
- Shanghai ChemPartner, 576 Libing
Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203, PRC
| | - Laura M. Dornan
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Sergio Duron
- Afraxis, Inc., 6605 Nancy Ridge
Road, Suite 224, San Diego, California 92121, United States
| | - Jennifer Epler
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Lewis Gazzard
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Christopher E. Heise
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Klaus P. Hoeflich
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Diana Jakubiak
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Hank La
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wendy Lee
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Baiwei Lin
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Joseph P. Lyssikatos
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jasna Maksimoska
- Perelman
School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States
| | - Ronen Marmorstein
- Perelman
School of Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104, United States
| | - Lesley J. Murray
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Thomas O’Brien
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Angela Oh
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Sreemathy Ramaswamy
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Weiru Wang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Xianrui Zhao
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Yu Zhong
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Elizabeth Blackwood
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Joachim Rudolph
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
10
|
Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 2015. [PMID: 26536114 DOI: 10.1038/nature16057.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Staphylococcus aureus is considered to be an extracellular pathogen. However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clinical failures and relapses after antibiotic therapy. Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus. This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome. The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteraemia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.
Collapse
Affiliation(s)
- Sophie M Lehar
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Thomas Pillow
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Min Xu
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Leanna Staben
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Kimberly K Kajihara
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Richard Vandlen
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Laura DePalatis
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Helga Raab
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Wouter L Hazenbos
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - J Hiroshi Morisaki
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Janice Kim
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Summer Park
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Martine Darwish
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Byoung-Chul Lee
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Hilda Hernandez
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Kelly M Loyet
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Patrick Lupardus
- Structural Biology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Rina Fong
- Structural Biology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Donghong Yan
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Cecile Chalouni
- Pathology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Elizabeth Luis
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Yana Khalfin
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Emile Plise
- Drug metabolism and Pharmacokinetics Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Jonathan Cheong
- Drug metabolism and Pharmacokinetics Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Joseph P Lyssikatos
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Magnus Strandh
- Symphogen A/S, Pederstrupvej 93, DK-2750 Ballerup, Denmark
| | - Klaus Koefoed
- Symphogen A/S, Pederstrupvej 93, DK-2750 Ballerup, Denmark
| | | | - John A Flygare
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Man Wah Tan
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Eric J Brown
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Sanjeev Mariathasan
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| |
Collapse
|
11
|
Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; 527:323-8. [PMID: 26536114 DOI: 10.1038/nature16057] [Citation(s) in RCA: 533] [Impact Index Per Article: 59.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 10/06/2015] [Indexed: 11/09/2022]
Abstract
Staphylococcus aureus is considered to be an extracellular pathogen. However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clinical failures and relapses after antibiotic therapy. Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus. This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome. The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteraemia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.
Collapse
Affiliation(s)
- Sophie M Lehar
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Thomas Pillow
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Min Xu
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Leanna Staben
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Kimberly K Kajihara
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Richard Vandlen
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Laura DePalatis
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Helga Raab
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Wouter L Hazenbos
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - J Hiroshi Morisaki
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Janice Kim
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Summer Park
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Martine Darwish
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Byoung-Chul Lee
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Hilda Hernandez
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Kelly M Loyet
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Patrick Lupardus
- Structural Biology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Rina Fong
- Structural Biology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Donghong Yan
- Translational Immunology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Cecile Chalouni
- Pathology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Elizabeth Luis
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Yana Khalfin
- Biochemical and Cellular Pharmacology Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Emile Plise
- Drug metabolism and Pharmacokinetics Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Jonathan Cheong
- Drug metabolism and Pharmacokinetics Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Joseph P Lyssikatos
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Magnus Strandh
- Symphogen A/S, Pederstrupvej 93, DK-2750 Ballerup, Denmark
| | - Klaus Koefoed
- Symphogen A/S, Pederstrupvej 93, DK-2750 Ballerup, Denmark
| | | | - John A Flygare
- Medicinal Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Man Wah Tan
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Eric J Brown
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| | - Sanjeev Mariathasan
- Infectious Diseases Department, Genentech Inc., South San Francisco, California 94080, USA
| |
Collapse
|
12
|
Wang X, Sun M, New C, Nam S, Blackaby WP, Hodges AJ, Nash D, Matteucci M, Lyssikatos JP, Fan PW, Tay S, Chang JH. Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System. ACS Med Chem Lett 2015; 6:925-9. [PMID: 26288695 DOI: 10.1021/acsmedchemlett.5b00191] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 07/12/2015] [Indexed: 12/17/2022] Open
Abstract
Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very challenging. Strategies to mitigate TDI are therefore highly valuable in discovering safe therapies to benefit patients. In this Letter, we disclose our simplified approach toward addressing CYP3A TDI liabilities, guided by metabolic mechanism hypotheses. By adding a methyl group onto the α carbon of a basic amine, TDI activities of both the truncated and full molecules (7a and 11) were completely eliminated. We propose that truncated molecules, albeit with caveats, may be used as surrogates for full molecules to investigate TDI.
Collapse
Affiliation(s)
- Xiaojing Wang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Minghua Sun
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Connie New
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Spencer Nam
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Wesley P. Blackaby
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Alastair J. Hodges
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - David Nash
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Mizio Matteucci
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Joseph P. Lyssikatos
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Peter W. Fan
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Suzanne Tay
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jae H. Chang
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
13
|
Fuji RN, Flagella M, Baca M, S. Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, Lyssikatos JP, O’Mahony J, Reichelt M, Roose-Girma M, Sheng Z, Sherer T, Smith A, Solon M, Sweeney ZK, Tarrant J, Urkowitz A, Warming S, Yaylaoglu M, Zhang S, Zhu H, Estrada AA, Watts RJ. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 2015; 7:273ra15. [DOI: 10.1126/scitranslmed.aaa3634] [Citation(s) in RCA: 242] [Impact Index Per Article: 26.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
14
|
Thomas AA, Hunt KW, Newhouse B, Watts RJ, Liu X, Vigers G, Smith D, Rhodes SP, Brown KD, Otten JN, Burkard M, Cox AA, Geck Do MK, Dutcher D, Rana S, DeLisle RK, Regal K, Wright AD, Groneberg R, Liao J, Scearce-Levie K, Siu M, Purkey HE, Lyssikatos JP. 8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J Med Chem 2014; 57:10112-29. [PMID: 25411915 DOI: 10.1021/jm5015132] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
A series of 2,3,4,4a,10,10a-hexahydropyrano[3,2-b]chromene analogs was developed that demonstrated high selectivity (>2000-fold) for BACE1 vs Cathepsin D (CatD). Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modulate potency, selectivity, efflux, and permeability. Guided by structure based design, changes to P2' and P3 moieties were explored. A conformationally restricted P2' methyl group provided inhibitors with excellent cell potency (37-137 nM) and selectivity (435 to >2000-fold) for BACE1 vs CatD. These efforts lead to compound 59, which demonstrated a 69% reduction in rat CSF Aβ1-40 at 60 mg/kg (PO).
Collapse
Affiliation(s)
- Allen A Thomas
- Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP, Le Pichon CE, Lin H, Liu W, Liu X, Liu Y, Ly CQ, Lyssikatos JP, Ma C, Scearce-Levie K, Shin YG, Solanoy H, Stark KL, Wang J, Wang B, Zhao X, Lewcock JW, Siu M. Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models. J Med Chem 2014; 58:401-18. [DOI: 10.1021/jm5013984] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Changyou Ma
- Department
of Chemistry, WuXi AppTec Co., Ltd., 288 Fute Zhonglu, Wai Gao Qiao Free
Trade Zone, Shanghai, 200131, P. R. China
| | | | | | | | | | - Jian Wang
- Department
of Chemistry, WuXi AppTec Co., Ltd., 288 Fute Zhonglu, Wai Gao Qiao Free
Trade Zone, Shanghai, 200131, P. R. China
| | | | | | | | | |
Collapse
|
16
|
Volgraf M, Chan L, Huestis MP, Purkey HE, Burkard M, Geck Do M, Harris J, Hunt KW, Liu X, Lyssikatos JP, Rana S, Thomas AA, Vigers GP, Siu M. Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors. Bioorg Med Chem Lett 2014; 24:2477-80. [DOI: 10.1016/j.bmcl.2014.04.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2014] [Revised: 04/01/2014] [Accepted: 04/04/2014] [Indexed: 10/25/2022]
|
17
|
Takahashi R, Ma S, Yue Q, Kim-Kang H, Yi Y, Lyssikatos JP, Regal K, Hunt KW, Kallan NC, Siu M, Hop CECA, Liu X, Khojasteh SC. Dose-dependent exposure and metabolism of GNE-892, a β-secretase inhibitor, in monkeys: contributions by P450, AO, and P-gp. Eur J Drug Metab Pharmacokinet 2014; 40:171-85. [DOI: 10.1007/s13318-014-0198-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 03/26/2014] [Indexed: 02/04/2023]
|
18
|
Thomas AA, Hunt KW, Volgraf M, Watts RJ, Liu X, Vigers G, Smith D, Sammond D, Tang TP, Rhodes SP, Metcalf AT, Brown KD, Otten JN, Burkard M, Cox AA, Do MKG, Dutcher D, Rana S, DeLisle RK, Regal K, Wright AD, Groneberg R, Scearce-Levie K, Siu M, Purkey HE, Lyssikatos JP, Gunawardana IW. Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system. J Med Chem 2014; 57:878-902. [PMID: 24397738 DOI: 10.1021/jm401635n] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In an attempt to increase selectivity vs Cathepsin D (CatD) in our BACE1 program, a series of 1,3,4,4a,10,10a-hexahydropyrano[4,3-b]chromene analogues was developed. Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modulate potency, selectivity, efflux, and permeability. Using structure-based design, substitutions to improve binding to both the S3 and S2' sites of BACE1 were explored. An acyl guanidine moiety provided the most potent analogues. These compounds demonstrated 10-420 fold selectivity for BACE1 vs CatD, and were highly potent in a cell assay measuring Aβ1-40 production (5-99 nM). They also suffered from high efflux. Despite this undesirable property, two of the acyl guanidines achieved free brain concentrations (Cfree,brain) in a guinea pig PD model sufficient to cover their cell IC50s. Moreover, a significant reduction of Aβ1-40 in guinea pig, rat, and cyno CSF (58%, 53%, and 63%, respectively) was observed for compound 62.
Collapse
Affiliation(s)
- Allen A Thomas
- Array BioPharma , 3200 Walnut Street, Boulder, Colorado 80301, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Estrada AA, Chan BK, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chen H, Dominguez SL, Dotson J, Drummond J, Flagella M, Fuji R, Gill A, Halladay J, Harris SF, Heffron TP, Kleinheinz T, Lee DW, Pichon CEL, Liu X, Lyssikatos JP, Medhurst AD, Moffat JG, Nash K, Scearce-Levie K, Sheng Z, Shore DG, Wong S, Zhang S, Zhang X, Zhu H, Sweeney ZK. Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors. J Med Chem 2014; 57:921-36. [DOI: 10.1021/jm401654j] [Citation(s) in RCA: 86] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Anthony A. Estrada
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Bryan K. Chan
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Charles Baker-Glenn
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Alan Beresford
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Daniel J. Burdick
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Mark Chambers
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Huifen Chen
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Sara L. Dominguez
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Jennafer Dotson
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Jason Drummond
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Michael Flagella
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Reina Fuji
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Andrew Gill
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Jason Halladay
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Seth F. Harris
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Timothy P. Heffron
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Tracy Kleinheinz
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Donna W. Lee
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Claire E. Le Pichon
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Xingrong Liu
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Joseph P. Lyssikatos
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Andrew D. Medhurst
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - John G. Moffat
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Kevin Nash
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Kimberly Scearce-Levie
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Zejuan Sheng
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Daniel G. Shore
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Susan Wong
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Shuo Zhang
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Xiaolin Zhang
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Haitao Zhu
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| | - Zachary K. Sweeney
- Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular
Pharmacology, ∥Drug Metabolism
and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
- Departments
of ∇Chemistry, ○Biochemical and
Cellular Pharmacology, and ◆Drug Metabolism
and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom
| |
Collapse
|
20
|
Hicken EJ, Marmsater FP, Munson MC, Schlachter ST, Robinson JE, Allen S, Burgess LE, DeLisle RK, Rizzi JP, Topalov GT, Zhao Q, Hicks JM, Kallan NC, Tarlton E, Allen A, Callejo M, Cox A, Rana S, Klopfenstein N, Woessner R, Lyssikatos JP. Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability. ACS Med Chem Lett 2014; 5:78-83. [PMID: 24900776 DOI: 10.1021/ml4003953] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 11/12/2013] [Indexed: 12/20/2022] Open
Abstract
The in silico construction of a PDGFRβ kinase homology model and ensuing medicinal chemistry guided by molecular modeling, led to the identification of potent, small molecule inhibitors of PDGFR. Subsequent exploration of structure-activity relationships (SAR) led to the incorporation of a constrained secondary amine to enhance selectivity. Further refinements led to the integration of a fluorine substituted piperidine, which resulted in significant reduction of P-glycoprotein (Pgp) mediated efflux and improved bioavailability. Compound 28 displayed oral exposure in rodents and had a pronounced effect in a pharmacokinetic-pharmacodynamic (PKPD) assay.
Collapse
Affiliation(s)
- Erik J. Hicken
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Fred P. Marmsater
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Mark C. Munson
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Stephen T. Schlachter
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - John E. Robinson
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Shelley Allen
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Laurence E. Burgess
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Robert Kirk DeLisle
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - James P. Rizzi
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - George T. Topalov
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Qian Zhao
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Julie M. Hicks
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Nicholas C. Kallan
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Eugene Tarlton
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Andrew Allen
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Michele Callejo
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - April Cox
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Sumeet Rana
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Nathalie Klopfenstein
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Richard Woessner
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| | - Joseph P. Lyssikatos
- Department of Drug Discovery, Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States
| |
Collapse
|
21
|
Lee W, Ortwine DF, Bergeron P, Lau K, Lin L, Malek S, Nonomiya J, Pei Z, Robarge KD, Schmidt S, Sideris S, Lyssikatos JP. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. Bioorg Med Chem Lett 2013; 23:5097-104. [PMID: 23932790 DOI: 10.1016/j.bmcl.2013.07.027] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Revised: 07/10/2013] [Accepted: 07/16/2013] [Indexed: 01/30/2023]
Abstract
A series of N-7-methyl-imidazolopyrimidine inhibitors of the mTOR kinase have been designed and prepared, based on the hypothesis that the N-7-methyl substituent on imidazolopyrimidine would impart selectivity for mTOR over the related PI3Kα and δ kinases. The corresponding N-Me substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines also show potent mTOR inhibition with selectivity toward both PI3α and δ kinases. The most potent compound synthesized is pyrazolo[4,3-d]pyrimidine 21c. Compound 21c shows a Ki of 2 nM against mTOR inhibition, remarkable selectivity (>2900×) over PI3 kinases, and excellent potency in cell-based assays.
Collapse
Affiliation(s)
- Wendy Lee
- Department of Discovery Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Hunt KW, Cook AW, Watts RJ, Clark CT, Vigers G, Smith D, Metcalf AT, Gunawardana IW, Burkard M, Cox AA, Geck Do MK, Dutcher D, Thomas AA, Rana S, Kallan NC, DeLisle RK, Rizzi JP, Regal K, Sammond D, Groneberg R, Siu M, Purkey H, Lyssikatos JP, Marlow A, Liu X, Tang TP. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species. J Med Chem 2013; 56:3379-403. [PMID: 23537249 DOI: 10.1021/jm4002154] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A hallmark of Alzheimer's disease is the brain deposition of amyloid beta (Aβ), a peptide of 36-43 amino acids that is likely a primary driver of neurodegeneration. Aβ is produced by the sequential cleavage of APP by BACE1 and γ-secretase; therefore, inhibition of BACE1 represents an attractive therapeutic target to slow or prevent Alzheimer's disease. Herein we describe BACE1 inhibitors with limited molecular flexibility and molecular weight that decrease CSF Aβ in vivo, despite efflux. Starting with spirocycle 1a, we explore structure-activity relationships of core changes, P3 moieties, and Asp binding functional groups in order to optimize BACE1 affinity, cathepsin D selectivity, and blood-brain barrier (BBB) penetration. Using wild type guinea pig and rat, we demonstrate a PK/PD relationship between free drug concentrations in the brain and CSF Aβ lowering. Optimization of brain exposure led to the discovery of (R)-50 which reduced CSF Aβ in rodents and in monkey.
Collapse
Affiliation(s)
- Kevin W Hunt
- Array BioPharma, 3200 Walnut Street, Boulder, CO 80301, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Estrada AA, Shore DG, Blackwood E, Chen YH, Deshmukh G, Ding X, DiPasquale AG, Epler JA, Friedman LS, Koehler MFT, Liu L, Malek S, Nonomiya J, Ortwine DF, Pei Z, Sideris S, St-Jean F, Trinh L, Truong T, Lyssikatos JP. Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). J Med Chem 2013; 56:3090-101. [DOI: 10.1021/jm400194n] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
| | | | | | | | | | | | - Antonio G. DiPasquale
- X-ray Crystallographic Facility, University of California—Berkeley, 32 Lewis
Hall, Berkeley, California 94720, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pei Z, Blackwood E, Liu L, Malek S, Belvin M, Koehler MT, Ortwine DF, Chen H, Cohen F, Kenny JR, Bergeron P, Lau K, Ly C, Zhao X, Estrada A, Truong T, Epler JA, Nonomiya J, Trinh L, Sideris S, Lesnick J, Bao L, Vijapurkar U, Mukadam S, Tay S, Deshmukh G, Chen YH, Ding X, Friedman L, Lyssikatos JP. Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett 2013; 4:103-7. [PMID: 24900569 PMCID: PMC4027466 DOI: 10.1021/ml3003132] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Accepted: 11/29/2012] [Indexed: 12/28/2022] Open
Abstract
Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.
Collapse
Affiliation(s)
- Zhonghua Pei
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Elizabeth Blackwood
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Lichuan Liu
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Shiva Malek
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Marcia Belvin
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Michael
F. T. Koehler
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Daniel F. Ortwine
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Huifen Chen
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Frederick Cohen
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Jane R. Kenny
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Philippe Bergeron
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Kevin Lau
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Cuong Ly
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Xianrui Zhao
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Anthony
A. Estrada
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Tom Truong
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Jennifer A. Epler
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Jim Nonomiya
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Lan Trinh
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Steve Sideris
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - John Lesnick
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Linda Bao
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Ulka Vijapurkar
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Sophie Mukadam
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Suzanne Tay
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Gauri Deshmukh
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Yung-Hsiang Chen
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Xiao Ding
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Lori
S. Friedman
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| | - Joseph P. Lyssikatos
- Departments
of Discovery Chemistry, Translational Oncology, DMPK, Biochemical and Cellular Pharmacology, and Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States
| |
Collapse
|
25
|
Koehler MFT, Bergeron P, Blackwood E, Bowman KK, Chen YH, Deshmukh G, Ding X, Epler J, Lau K, Lee L, Liu L, Ly C, Malek S, Nonomiya J, Oeh J, Ortwine DF, Sampath D, Sideris S, Trinh L, Truong T, Wu J, Pei Z, Lyssikatos JP. Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity. J Med Chem 2012. [PMID: 23199076 DOI: 10.1021/jm301389h] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with K(i) < 10 nM for the mTOR kinase and >500-fold selectivity over closely related PI3 kinases. This potency translated into strong pathway inhibition, as measured by phosphorylation of mTOR substrate proteins and antiproliferative activity in cell lines with a constitutively active PI3K pathway. Two compounds exhibiting suitable mouse PK were profiled in in vivo tumor models and were shown to suppress mTORC1 and mTORC2 signaling for over 12 h when dosed orally. Both compounds were additionally shown to suppress tumor growth in vivo in a PC3 prostate cancer model over a 14 day study.
Collapse
Affiliation(s)
- Michael F T Koehler
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA, Kenny JR, Kulagowski J, Lee L, Magnuson SR, Morris C, Murray J, Pastor RM, Rawson T, Siu M, Ultsch M, Zhou A, Sampath D, Lyssikatos JP. Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors. J Med Chem 2012; 55:10090-107. [DOI: 10.1021/jm3012239] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
| | | | | | | | | | | | | | - Sean Flynn
- Argenta,
8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | | | - Christopher A. Hurley
- Argenta,
8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | | | - Janusz Kulagowski
- Argenta,
8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | | | | | - Claire Morris
- Argenta,
8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, United Kingdom
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Estrada AA, Liu X, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chan BK, Chen H, Ding X, DiPasquale AG, Dominguez SL, Dotson J, Drummond J, Flagella M, Flynn S, Fuji R, Gill A, Gunzner-Toste J, Harris SF, Heffron TP, Kleinheinz T, Lee DW, Le Pichon CE, Lyssikatos JP, Medhurst AD, Moffat JG, Mukund S, Nash K, Scearce-Levie K, Sheng Z, Shore DG, Tran T, Trivedi N, Wang S, Zhang S, Zhang X, Zhao G, Zhu H, Sweeney ZK. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 2012; 55:9416-33. [PMID: 22985112 DOI: 10.1021/jm301020q] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.
Collapse
Affiliation(s)
- Anthony A Estrada
- Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Cohen F, Bergeron P, Blackwood E, Bowman KK, Chen H, DiPasquale AG, Epler JA, Koehler MFT, Lau K, Lewis C, Liu L, Ly CQ, Malek S, Nonomiya J, Ortwine DF, Pei Z, Robarge KD, Sideris S, Trinh L, Truong T, Wu J, Zhao X, Lyssikatos JP. Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine. J Med Chem 2011; 54:3426-35. [PMID: 21495671 DOI: 10.1021/jm200215y] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | | | | | - Antonio G. DiPasquale
- X-ray Crystallography Facility, University of California Berkeley, 32 Lewis Hall Berkeley, California 94720, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Hanan EJ, Chan BK, Estrada AA, Shore DG, Lyssikatos JP. ChemInform Abstract: Mild and General One-Pot Reduction and Cyclization of Aromatic and Heteroaromatic 2-Nitroamines to Bicyclic 2H-Imidazoles. ACTA ACUST UNITED AC 2011. [DOI: 10.1002/chin.201111140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
30
|
Abstract
This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.
Collapse
Affiliation(s)
- Eli M Wallace
- Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA.
| | | | | | | | | |
Collapse
|
31
|
Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 2005; 65:957-66. [PMID: 15705896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
CP-673,451 is a potent inhibitor of platelet-derived growth factor beta-receptor (PDGFR-beta) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-beta in cells (IC(50) = 1 nmol/L) being more than 450-fold selective for PDGFR-beta versus other angiogenic receptors (e.g., vascular endothelial growth factor receptor 2, TIE-2, and fibroblast growth factor receptor 2). Multiple models have been used to evaluate in vivo activity of CP-673,451 and to understand the pharmacology of PDGFR-beta inhibition and the effect on tumor growth. These models include an ex vivo measure of PDGFR-beta phosphorylation in glioblastoma tumors, a sponge model to measure inhibition of angiogenesis, and multiple models of tumor growth inhibition. Inhibition of PDGFR-beta phosphorylation in tumors correlates with plasma and tumor levels of CP-673,451. A dose of 33 mg/kg was adequate to provide >50% inhibition of receptor for 4 hours corresponding to an EC(50) of 120 ng/mL in plasma at C(max). In a sponge angiogenesis model, CP-673,451 inhibited 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg (q.d. x 5, p.o., corresponding to 5.5 ng/mL at C(max)). The compound did not inhibit vascular endothelial growth factor- or basic fibroblast growth factor-induced angiogenesis at concentrations which inhibited tumor growth. The antitumor efficacy of CP-673,451 was evaluated in a number of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiforme. Once-daily p.o. x 10 days dosing routinely inhibited tumor growth (ED(50) < or = 33 mg/kg). These data show that CP-673,451 is a pharmacologically selective PDGFR inhibitor, inhibits tumor PDGFR-beta phosphorylation, selectively inhibits PDGF-BB-stimulated angiogenesis in vivo, and causes significant tumor growth inhibition in multiple human xenograft models.
Collapse
Affiliation(s)
- W Gregory Roberts
- Pfizer Oncology, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E. Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451. Cancer Res 2005. [DOI: 10.1158/0008-5472.957.65.3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CP-673,451 is a potent inhibitor of platelet-derived growth factor β-receptor (PDGFR-β) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-β in cells (IC50 = 1 nmol/L) being more than 450-fold selective for PDGFR-β versus other angiogenic receptors (e.g., vascular endothelial growth factor receptor 2, TIE-2, and fibroblast growth factor receptor 2). Multiple models have been used to evaluate in vivo activity of CP-673,451 and to understand the pharmacology of PDGFR-β inhibition and the effect on tumor growth. These models include an ex vivo measure of PDGFR-β phosphorylation in glioblastoma tumors, a sponge model to measure inhibition of angiogenesis, and multiple models of tumor growth inhibition. Inhibition of PDGFR-β phosphorylation in tumors correlates with plasma and tumor levels of CP-673,451. A dose of 33 mg/kg was adequate to provide >50% inhibition of receptor for 4 hours corresponding to an EC50 of 120 ng/mL in plasma at Cmax. In a sponge angiogenesis model, CP-673,451 inhibited 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg (q.d. × 5, p.o., corresponding to 5.5 ng/mL at Cmax). The compound did not inhibit vascular endothelial growth factor- or basic fibroblast growth factor-induced angiogenesis at concentrations which inhibited tumor growth. The antitumor efficacy of CP-673,451 was evaluated in a number of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiforme. Once-daily p.o. × 10 days dosing routinely inhibited tumor growth (ED50 ≤ 33 mg/kg). These data show that CP-673,451 is a pharmacologically selective PDGFR inhibitor, inhibits tumor PDGFR-β phosphorylation, selectively inhibits PDGF-BB-stimulated angiogenesis in vivo, and causes significant tumor growth inhibition in multiple human xenograft models.
Collapse
Affiliation(s)
- W. Gregory Roberts
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Pamela M. Whalen
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Erik Soderstrom
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Garrett Moraski
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | | | - Huifen-F. Wang
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Beth Cooper
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Deborah A. Baker
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Douglas Savage
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Deepak Dalvie
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - James A. Atherton
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Sherry Ralston
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Ruby Szewc
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - John C. Kath
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Jing Lin
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Cathy Soderstrom
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - George Tkalcevic
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Bruce D. Cohen
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Vince Pollack
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Wayne Barth
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Will Hungerford
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| | - Ethan Ung
- Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut
| |
Collapse
|
33
|
Andresen BM, Couturier M, Cronin B, D'Occhio M, Ewing MD, Guinn M, Hawkins JM, Jasys VJ, LaGreca SD, Lyssikatos JP, Moraski G, Ng K, Raggon JW, Stewart AM, Tickner DL, Tucker JL, Urban FJ, Vazquez E, Wei L. Streamlined Processes for the Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate. Org Process Res Dev 2004. [DOI: 10.1021/op049935g] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | - Michel Couturier
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Brian Cronin
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Michael D'Occhio
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Marcus D. Ewing
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Mark Guinn
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Joel M. Hawkins
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - V. John Jasys
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Susan D. LaGreca
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | | | - Garrett Moraski
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Karl Ng
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | | | | | - Derek L. Tickner
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - John L. Tucker
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Frank J. Urban
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Enrique Vazquez
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| | - Lulin Wei
- Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, U.S.A
| |
Collapse
|
34
|
Coleman KG, Lyssikatos JP, Yang BV. Chapter 17. Chemical Inhibitors of Cyclin-dependent Kinases. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1997. [DOI: 10.1016/s0065-7743(08)61475-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/14/2023]
|
35
|
|
36
|
Lyssikatos JP, Bednarski MD. An Anomalous Case of Diastereoselectivity in Diels-Alder Reactions Using Chiral Dienes: Is π Stacking Involved? Synlett 1990. [DOI: 10.1055/s-1990-21047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|